Search results
Showing 46 to 60 of 109 results for melanoma
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)
This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.
In development Reference number: GID-TAG509 Expected publication date: 28 September 2016
which imaging modality should be used for people with stage IIB to IIIC melanoma? Any explanatory notes(if applicable) For a short...
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
Awaiting development Reference number: GID-TA11929 Expected publication date: TBC
vemurafenib and ipilimumab in patients who have BRAF V600 mutation-positive melanoma. Any explanatory notes(if applicable) This may...
Question Vitamin D supplementation: In people with stage I to III melanoma does vitamin D supplementation improve overall survival? This...
Ixekizumab for treating moderate to severe plaque psoriasis (TA442)
Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults.
Cancer of the upper aerodigestive tract: assessment and management in people aged 16 or over (NG36)
This guideline covers assessing and managing cancers of the upper aerodigestive tract in people aged 16 or over. These are cancers of the airways of the head and neck, including the mouth, throat, larynx (voicebox) and sinuses. The guideline aims to reduce variation in practice and improve survival.
Evidence-based recommendations on endoscopic radical inguinal lymphadenectomy. This involves using an endoscopic device and small incisions to reduce discomfort, scarring and complications associated with inguinal lymph node removal.
View recommendations for HTG265Show all sections
Sections for HTG265
Evidence-based recommendations on lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema in adults. This involves diverting some of the lymphatic vessels around where lymph nodes have been removed to nearby veins.
View recommendations for HTG717Show all sections
Discontinued Reference number: GID-IP1041
Evidence-based recommendations on nivolumab (Opdivo) plus ipilimumab (Yervoy) for untreated unresectable or metastatic colorectal cancer with high microsatellite instability in adults.
Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]
Awaiting development Reference number: GID-TA11458 Expected publication date: TBC
Interstitial photodynamic therapy for malignant parotid tumours (HTG166)
Evidence-based recommendations on interstitial photodynamic therapy for malignant parotid tumours. This involves injecting a photosensitising agent into a vein and using a special light to activate it and destroy the tumour cells.
View recommendations for HTG166Show all sections
Sections for HTG166